Conference abstractPublished 6 Aug 2025
Does the NLRP3 inflammasome drive inflammation in PCOS? Insights from human adipose tissue
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Polycystic ovary syndrome (PCOS) is a complex endocrine-metabolic condition affecting reproductive and metabolic health in women of reproductive age. Chronic low-grade inflammation is a key feature of PCOS, but its molecular drivers remain poorly understood. Among candidate mechanisms, the NLRP3 inflammasome, a central regulator of innate immune-mediated inflammation, has emerged as a potential contributor to PCOS pathology. What was the key research question? Does the NLRP3 inflammasome play a role in the pathogen esis of PCOS? This study aimed to investigate whether the expression of NLRP3 and its associated inflammasome components is altered in the adipose tissue of women with PCOS, providing molecular insight into its potential involvement in disease mechanisms. What was known before? The NLRP3 inflammasome is activated in metabolic disorders such as obesity and type 2 diabetes, both of which are common in PCOS. It governs the maturation of IL-1β and IL 18, pro-inflammatory cytokines implicated in insulin resistance and systemic inflammation. While increased inflammasome activity has been reported in blood samples from PCOS patients, its status in adipose tissue, a metabolically active and immunologically relevant organ, has not been clearly defined. What was done in this study? In a case-control study, subcutaneous and visceral adipose tissue (SAT and VAT) biopsies were collected from PCOS patients and BMI-matched healthy controls. RT-qPCR was used to measure the mRNA expression of key inflammasome genes: NLRP3, IL-1B, CASP1, and PYCARD. What were the main findings and role of chance? No significant differences in gene expression of NLRP3 or its related components were observed between PCOS and control groups (all p>0.05). These findings suggest that NLRP3 is not transcriptionally upregulated in the adipose tissue of women with PCOS. However, the study's conclusions are tempered by potential limitations including sample size, adipose tissue variability, and the known disconnect between mRNA expression and protein function in inflammasome biology. What is the interpretation and next step? Although no transcriptional activation of the NLRP3 inflammasome was observed, this does not exclude a role for NLRP3 in PCOS pathogenesis. Functional validation using protein-level assays (e.g., Western blotting) and inflammasome activation studies are essential to determine whether post transcriptional or post-translational regulation may still drive inflammatory signalling in PCOS. Conclusion: This study provides preliminary evidence that NLRP3 gene expression is not elevated in adipose tissue from PCOS women. Nonetheless, the broader question of its role in PCOS remains open and warrants further investigation through multi-level molecular and functional studies to clarify its contribution and therapeutic potential.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Steroids & Hormonal Science
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Salih Atalah Alenezi”